Abstract:Dear Editor, Chronic hepatitis B virus (HBV) infection affects about 844 million people worldwide, with two million annual deaths and a rising incidence. Persistent HBV infection may lead to liver inflammation and fibrosis, a leading risk for liver transplantation and hepatocellular carcinoma.1 However, few treatment options for controlling HBV-related liver inflammation are currently available. The limited understanding on corresponding mechanisms impedes the discovery of rational therapeutics targeting on liver inflammation and fibrosis. Thus, we conducted a single-cell transcriptomic study2 to better understand the mechanisms underlying chronic HBV-related liver inflammation and to enable the discovery of therapeutic targets. Liver biopsies from six chronic HBV patients with different grades of liver inflammation were included in the present study (Figure S1; Table S1). Single-cell RNA sequencing of biopsied liver tissues was performed. Functions and cross-talks of single cells were also investigated (provided in Supplementary Materials). Based on around 24,000 single cells, we obtained 12 cell clusters. Among them, T cell population was the most abundant (Figure 1; Figure S2). By assigning the samples to different grades of inflammation (G), no apparent perturbation was observed in respect to the fractions of cells between grades G1 and G2 (Table S2). We further classified the 16, 386 T cells into nine cell subclusters, six of which varied significantly as liver inflammation progresses (Figure 2A,B). We then assigned them to known lineages based on marker genes (Figure 2C,D; Table S3). Concisely, T7 and T6 were annotated as CD8+ mucosal-associated invariant T (MAIT) cells. T2 and T0 were identified as activated and exhausted CD8+ T cells, respectively. Most interestingly, MAIT cells, especially T7, decreased, while the ratio of T6 versus T7 increased in grade G2. Moreover, T7 dominated in grade G1 (95.20%) (Figure 2E and Figure S3A,B). The above findings were confirmed by additional single-cell RNA sequencing data from liver samples of HBV-infected patients with grades G1 (n = 4) and G2 (n = 4) (Figure S3C,D).2 T6 was assumed to be developed from T7 (Figure 2F), with genes such as CCL3L1, PTMS, KLRG1 and GADD45B responsible for the transition (Figure S3E). Additionally, macrophage subcluster Ma3, inclined to have M2 signature, increased in grade G2 (Figure S4). Although no apparent perturbations were observed for the fractions of different cell types, T cell subpopulations were remodeled during the progression from grades G1 to G2. We further confirmed the presence of two MAIT cell populations by immunofluorescence, and annotated them as CD3+SLC4A10+TNFAIP3+ (T7) and CD3+SLC4A10+TNFAIP3− (T6) MAIT cells (Figure 3). T7 may have stronger direct anti-viral functions. Firstly, intrahepatic MAIT cells have been reported to be the most important innate effector cells secreting anti-viral cytokine IFN-γ,3 and T7 demonstrated up-regulated pathways ‘interferon gamma secretion’ and ‘regulation of response to interferon gamma’ (Figure 4A). Secondly, T7 may have stronger type-17 function of MAIT cell populations that might have a certain antiviral role,4 evidenced by the up-regulation of pathways such as ‘T helper 17 type immune response’. Moreover, T7 may be stronger mediators of immune responses. On one hand, T7 may increase the anti-viral capability of hepatocytes by ligand-receptor pairs such as ‘FcRn complex_ALB’ (Figure 4B), where FcRn was reported to increase the sensitivity of hepatocyte to toxicity.5 Pathways such as ‘Toll-like receptor 4 signaling pathways’ that can reduce HBV replication in an IFN-independent manner in hepatocytes6 was also up-regulated in T7. On the other hand, T7 may be more active in cytokine production and recruiting activated CD4+ and CD8+ T cells,7 evidenced by up-regulated pathways such as ‘positive regulation of CD4 positive alpha beta T cell activation’. Then, T7 may assist virus infection control via activating NK cell and CD8+ T cell mediated immune responses through cross-talks for T7-NK cells and T7-T2, evidenced by ligand-receptor pairs such as ‘HLA-C_KIR2DL3’ and ‘HLA-A_KIR3DL1’, which were reported to function as helper masters to antiviral T cell responses.8 Such results indicated that MAIT cell population T7 may have active antiviral functions for reducing HBV replication in grade G1. Immunofluorescence results for additional two biopsies obtained from two G1 patients (Figure S5) further validated the presence of T7 in grade G1. We speculated impaired antiviral roles of T6 in grade G2 from the down-regulation of corresponding pathways mentioned above, and the decrease in pathways ‘regulation of defense response to virus’ and ‘innate immune response’ (Figure 4A). Such results implied the existence of MAIT cell dysfunction in grade G2. We also observed a sharp decrease of activated CD8+ T cells, and a sharp increase of CD8+ exhausted T cells in grade G2. T cell exhaustion, in together with immune dysfunction of T6, may contribute to the inadequate HBV-specific immune responses and inadequate infection control in grade G2. The increased M2-type macrophage activation (Ma3) also implied the impaired immune response9 in grade G2. Bacterial superantigens resulting from the leaky gut of chronic HBV patients can make MAIT cells hyperactive and exhausted, which will lead to immunosuppression and increases the risk of secondary opportunistic infections.10 Thus, the dysfunction of MAIT cells T6 and exhaustion of CD8+ T cells may also provide an explanation for the progression of HBV-related inflammation in grade G2. Moreover, MAIT cells demonstrated extensive interactions with other immune cells (provided in Supplementary Materials). In conclusion, our study reported the remodelling of T cell subpopulations and the presence of two MAIT cell populations that may contribute to HBV-related liver inflammation for the first time. MAIT cell population T7 may have active roles in assisting virus clearance via direct anti-viral functions and mediating immune responses, which was impaired in T6, the proportion of which in CD8+ MAIT cells increased in grade G2. The sharp decrease of active CD8+ T cells, MAIT cell dysfunction in together may contribute to the inadequate HBV-specific immune responses in grade G2. Inspired from the decrease of MAIT cells and increased ratio of T6 versus T7 during liver inflammation progression, MAIT cells may act as a potential target for controlling HBV-related liver inflammation in future studies. However, studies using more samples are required to confirm the findings between G1 and G2 reported in this study. The present study was funded by grants from the National Natural Science Foundation of China (grant numbers: 31870839 and 81870426), the Natural Science Foundation of Zhejiang Province (grant numbers: LZ20H290002 and LY22C010001), the National Youth Top-notch Talent Support Program (grant number: W02070098), the HangZhou Medical and Health Technology Project (grant number: Z20200052), and the Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine (grant number: ZYYCXTD-D-202002). The authors declare that they have no conflict of interest. This work was supported by the key medical disciplines of Hangzhou and the Westlake Laboratory (Westlake Laboratory of Life Sciences and Biomedicine). The authors thank all the participants who helped collecting liver biopsies. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

Abstract:Hepatitis B virus (HBV) infection, which affects 90 million people in China, remains a prominent cause of liver cancer and liver cirrhosis.[1] Chronic HBV infection has a complicated course, which is a dynamic process formed by the interaction between the virus and the immune system.[2,3] Hepatic fibrosis is the basis of liver cirrhosis and liver cancer.[4] In recent years, accumulating studies have indicated potential roles of intestinal microbiota, bile acids, and T helper (Th)17/ interleukin (IL)-17 axis in the process of HBV-related liver fibrosis. Gut microbiota actively communicates with bile acids and plays an important role in the pathogenesis of HBV-related liver fibrosis. In the following content, we are going to summarize current evidence of the role of intestinal microbiota, bile acids, and Th17/IL-17 axis in HBV-related liver fibrosis. Age at the time of infection is an important factor affecting the immune response after HBV infection, and its mechanism may be related to the establishment of mature intestinal microbiota. In HBV transfected mouse models, virus clearance was substantially dependent on the formation of mature intestinal microbiota. Adult mice with mature and stable intestinal microbiota could completely clear the virus within 6 weeks after HBV plasmid injection, while young mice with immature intestinal microbiota could have the virus persistent after 6 weeks. Antibiotics treatment could delay the clearance of HBV in adult mice.[5] From another perspective, controlled clinical study of chronic HBV infection patients, the combination of nucleoside antiviral drugs with fecal microbiota transplantation could significantly reduce HBV viral load, increase HBV E antigen conversion, and improve liver function.[6] Taken together, it could be inferred that intestinal microbiota is involved in the immune response process of HBV virus clearance, while the specific mechanism remains unclear. Th17 cells, as a subset of helper T cells, play an important role in chronic inflammation and immune-related diseases. Th17 cells could secrete inflammatory cytokines such as IL-17 and IL-22, which can activate hepatic stellate cells and Kupffer cells. This may promote the synthesis and accumulation of extracellular matrix, and further contribute to the process of liver fibrosis.[7] Chronic hepatic fibrosis diseases, such as alcoholic liver disease, autoimmune hepatitis, primary sclerosing cholangitis, primary biliary cirrhosis, biliary atresia, nonalcoholic fatty liver disease, and viral hepatitis, have been observed with increased peripheral Th17 cell count.[8] A number of studies have found that chronic HBV infected patients are accompanied by increased number of Th17 cells in peripheral circulation and liver tissue, together with alterations of related cytokines. In chronic HBV infected patients, the number of peripheral Th17 cells was significantly higher than that of the control group, and was positively correlated with the level of serum alanine aminotransferase (ALT).[9] The level of Th17 cell infiltration to liver tissues of chronic HBV infection patients is also positively correlated with the severity of liver inflammation and fibrosis.[10] After antiviral therapy with nucleoside analogs, the level of Th17 cells and IL-17 in peripheral blood of chronic HBV infection patients declines with viral load.[11] Th17 cells in liver tissue might not differentiate in situ, but mainly migrate based on local signals in the liver parenchyma. HBV infection can induce Th17 cells to migrate from peripheral to hepatic tissue by upregulation of chemokines such as chemokine C-C motif ligand (CCL) 17, CCL20, and CCL22 in hepatocytes. In comparison with uninfected controls, the mRNA levels of hepatocellular chemokines CCL17 and CCL22 were significantly increased in patients with chronic HBV infection, as well as increased expression of chemokine receptors 6 (CCR6) and chemokine receptor 4 (CCR4) on Th17 cells. In vitro experiments also confirmed that HBV DNA could induce hepatocytes to express Th17 chemokines CCL17 and CCL22.[12] The most possible source of Th17 cells is the intestinal lamina propria, which contains a large number of CD4+ T cells, primarily Th17 cells and regulatory T cell (Treg) cells.[13] Intestinal microbiota maintains immune regulation function by changing the balance of Th17/Treg cells.[14] Th17 cells of specific pathogen-free (SPF) mouse were mainly observed in the ileum and colonic lamina, which also contain the highest density of bacteria. There are relatively few Th17 cells in the duodenum, jejunum, mesenteric lymph nodes, spleen, or liver.[15] In comparison with SPF mice, germ-free mice contained fewer Th17 cells in the intestinal lamina propria; moreover, after transplanting intestinal microbiota from normal mice to germ-free mice, the intestinal Th17 cell content increased accordingly.[16] Low-dose penicillin exposure early after birth can change the composition of intestinal microbiota, thus influencing the differentiation of Th17 cells and the expression of pro-inflammatory factor IL-17.[17] On the other hand, vancomycin added to drinking water significantly reduced Th17 cell levels in the lung.[18] The differentiation of Th17 cells depends on the stimulation of symbiotic intestinal bacteria. However, whether the microbes interact with CD4+ T cells directly remains unclear. Some intestinal microbes have been found to be related to the differentiation of Th17 cells directly, such as segmented filamentous bacteria, Citrobacter Rodentium, and Escherichia coli O 157.[19] Besides, twenty mixed strains isolated from fecal flora could also stimulate the differentiation of intestinal Th17 cells. Then, further 16S rRNA sequencing analysis showed that the 20 strains were derived from Clostridium, Bifidobacterium, Ruminococcus, and Bacteroides.[20] Intestinal commensal Bacteroides species peptide derivatives could specifically stimulate the differentiation of intestinal Th17 cells and participate in the development of myocarditis.[21] Although previous results have suggested a direct interaction between intestinal bacteria and Th17 cells, several lines of evidence have proposed that the stimulation might be mediated by the intestinal bile acids pool. Intestinal bacteria could produce choline dehydrogenase and steroid dehydrogenase, which can affect bile acids metabolism, covalent modification and isomerization, and participate in the formation of secondary bile acids.[22] Intestinal secondary bile acids can stimulate intestinal epithelial or lamina propria immune cells to produce inflammatory regulatory factors, which directly influence subsequent immune response.[23] Hang et al[24] screened more than 30 bile acid metabolites and identified two lithocholic acid derivatives, 3-oxo lithocholic acid (LCA) and isoallo LCA, which can reduce the differentiation of Th17 cells and increase the differentiation of Treg cells. The regulatory effect of intestinal bile acids pool on adaptive immunity was also observed in another study, which found that the composition of the intestinal bile acids pool can regulate the expression of the transcription factor retinoic acid receptor-related-orphan-receptor-C (RORγ) on colonic forkhead box protein P3+ (FOXP3+) Treg cells. The deletion of bile acids metabolic pathway significantly reduced the number of intestinal Treg cells, while the restoration of the intestinal bile acids pool showed increased the number of ROR+ Treg cells in the colon and improvement of the host colon inflammation.[25] Thus, it can be inferred that the intestinal bile acids pool may be involved in mediating the regulatory role of intestinal bacteria on Th17 cell differentiation. Based on the evidence presented, we proposed a potential scientific hypothesis on the mechanism of HBV-related liver fibrosis [Figure 1]. Distinct gut microbiota in chronic HBV infection may lead to alterations of gut bile acids pool, then stimulate naive T cells to differentiate into Th17 cells, which then enter peripheral circulation and migrate to the liver via chemokine CCL20. Intrahepatic Th17 cells then secrete IL-17 and IL-22, which would activate hepatic stellate cells and Kupffer cells, and then lead to over-synthesis of the extracellular matrix. Although, there is still much to uncover for the specific mechanisms. With further research, the therapeutic potential of targeting the bile acids-intestinal microbiota-Th17/IL-17 axis will allow us to better discern the pathogenesis and treatment of HBV.Figure 1: Possible relationship among intestinal microbiota, bile acids, and Th17/IL-17 axis in HBV-related liver fibrosis. Distinct gut microbiota in chronic HBV infection may lead to alterations of gut bile acids pool, then stimulate naive T cells to differentiate into Th17 cells, which then enter peripheral circulation and migrate to the liver via chemokine CCL20. Intrahepatic Th17 cells then secrete IL-17 and IL-22, which would activate hepatic stellate cells and Kupffer cells, lead to over-synthesis of the extracellular matrix. Th: T helper; IL: interleukin; HBV: Hepatitis B virus; CCL: C-C motif ligand.Acknowledgements We thank Maria Antony (University of Connecticut Health Center) for the help in language editing. Conflicts of interest None.

Alterations in gut microbiome and metabolomics in chronic hepatitis B infection-associated liver disease and their impact on peripheral immune response

Biopsy‐based Single‐cell Transcriptomics Reveals MAIT Cells As Potential Targets for Controlling Fibrosis‐related Liver Inflammation Due to Chronic Hepatitis‐b Infection

Gut Microbial Dysbiosis is Associated with Altered Hepatic Functions and Serum Metabolites in Chronic Hepatitis B Patients.

Characterization of the Circulating Microbiome in Acute-on-chronic Liver Failure Associated with Hepatitis B.

Changes of Fecal Bifidobacterium Species in Adult Patients with Hepatitis B Virus-Induced Chronic Liver Disease

Gut microbiota of hepatitis B virus-infected patients in the immune-tolerant and immune-active phases and their implications in metabolite changes

Intestinal Microbiota Was Assessed in Cirrhotic Patients with Hepatitis B Virus Infection

Gut microbiota dysbiosis in patients with hepatitis B virus–induced chronic liver disease covering chronic hepatitis, liver cirrhosis and hepatocellular carcinoma

Gut microbiota dysbiosis with hepatitis B virus liver disease and association with immune response

Decreased Diversity of the Oral Microbiota of Patients with Hepatitis B Virus-Induced Chronic Liver Disease: A Pilot Project

Impact of the Gut Microbiome on the Progression of Hepatitis B Virus Related Acute-on-Chronic Liver Failure

Featured Gut Microbiomes Associated with the Progression of Chronic Hepatitis B Disease

Alteration of Gut Microbiota and Its Impact on Immune Response in Patients with Chronic HBV Infection: A Review

Distinct Bile Acid Profiles in Patients With Chronic Hepatitis B Virus Infection Reveal Metabolic Interplay Between Host, Virus and Gut Microbiome

Changes in Intestinal Microflora in Patients with Chronic Severe Hepatitis

Gut Microbiome Signatures in the Progression of Hepatitis B Virus-Induced Liver Disease

Serum metabolomic signatures discriminate early liver inflammation and fibrosis stages in patients with chronic hepatitis B

The Role of Intestinal Microbiota, Bile Acids, and Th17/IL17 Axis in Hepatitis B Virus-Related Liver Fibrosis

IDDF2018-ABS-0161 Gut Microbiome Across Stages of HBV Infection

Effect of Additional Clostridium butyricum on the Intestinal Flora of Chronic Hepatitis B Patients Treated with Entecavir

Circulating Proteomic Panels For Diagnosis And Risk Stratification Of Acute-On-Chronic Liver Failure In Patients With Viral Hepatitis B